Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus MINOCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus MINOCIN.
ACHROMYCIN vs MINOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Minocycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
100 mg orally or intravenously every 12 hours for 24 hours, then 100 mg every 12 hours; severe infections: 200 mg initially, then 100 mg every 12 hours.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life is 11–17 hours in patients with normal renal function; prolonged up to 18–69 hours in renal impairment.
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Primarily renal (approximately 70% unchanged) and biliary/fecal (approximately 30%, with enterohepatic recycling).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic